Beyond the Old Paradigms: Novel Approaches to the Treatment of Chronic Idiopathic ConstipationPremiere Date: Wednesday, August 19, 2020
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, August 19, 2021
Note: Credit Is No Longer Available
|Anthony J. Lembo, MD (Moderator)
Professor of Medicine
Harvard Medical School
Director, GI Motility Laboratory
Division of Gastroenterology
Beth Israel Deaconess Medical Center
|William D. Chey, MD, AGAF, FACG, FACP
Timothy T. Nostrant Collegiate Professor of Gastroenterology
Professor of Nutrition Sciences
Chief, Division of Gastroenterology & Hepatology
Departments of Internal Medicine and Nutritional Sciences
University of Michigan
Ann Arbor, MI
|Douglas A. Drossman, MD
President, Drossman Center for the Education and Practice of Biopsychosocial Care LLC
President, Drossman Consulting LLC
President Emeritus and COO, Rome Foundation
Professor Emeritus of Medicine and Psychiatry
University of North Carolina School of Medicine
Former Co-Director, UNC Center for Functional GI and Motility Disorders
Chronic idiopathic constipation (CIC) affects 35 million adults in the United States, making it one of the most common gastrointestinal disorders. Despite the high prevalence, CIC is often underdiagnosed and undertreated, which exacts a functional, psychosocial, and economic toll on patients and their loved ones. The current treatment goal in CIC is multi-symptom relief, but only 16% of patients with CIC are on prescription therapy, and they often only obtain partial relief, with many using laxatives on a regular basis without medical supervision.
This CME Outfitters OnDemand features evidence-based dialogue that focuses on guideline recommendations for diagnosing patients with CIC, assessing the efficacy and safety of novel pharmacotherapeutic options, and implementing strategies for multidisciplinary collaboration, with the goal of providing full relief to patients with CIC.
At the end of this CE activity, participants should be able to:
- Follow guideline recommendations to diagnose patients with CIC and set appropriate treatment goals.
- Assess efficacy and safety of novel pharmacotherapeutic options in order to provide full relief to patients with CIC.
- Implement strategies for multidisciplinary collaboration and care coordination in order to achieve treatment goals and improve patient outcomes.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify guideline recommendations for diagnosing patients with CIC.
- Assess efficacy and safety of novel pharmacotherapeutic options for providing full relief to patients with CIC.
- Describe strategies for multidisciplinary collaboration and care coordination for achieving treatment goals and improved patient outcomes.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Gastroenterologists, PAs, nurse practitioners, nurses, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Lembo reports that he receives research support from: Ironwood Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Vanda Pharmaceuticals Inc. He is on the advisory committee for Cara Care. He is a consultant for Ardelyx; Ironwood Pharmaceuticals, Inc; Mylan; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and Vibrant Pharma Inc.
Dr. Chey reports that he receives grants and research support from Biomerica, Inc.; Commonwealth Diagnostics International, Inc.; QOL Medical; Urovant Sciences, Inc.; Vibrant Pharma Inc.; and Zespri. He is a consultant for AbbVie Inc./Allergan; Alnylam Pharmaceuticals Inc.; Arena Pharmaceuticals, Inc.; Biomerica, Inc.; Gemelli Biotech; IM Health; Ironwood Pharmaceuticals, Inc.; Phathom Pharmaceuticals; Progenity, Inc.; QOL Medical; RedHill Biopharma Inc.; Ritter Pharmaceuticals Inc.; Salix Pharmaceuticals/Valeant Pharmaceuticals; Urovant Sciences, Inc.; and Vibrant Pharma Inc. He is a stock shareholder (directly purchased) for Options: GI OnDEMAND; ModifyHealth, LLC; and Ritter Pharmaceuticals Inc.
Dr. Drossman has no disclosures to report.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Olga Askinazi, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).